The human body harbours trillions of microbes, known collectively as the “human microbiome.” By far the highest density of commensal bacteria is found in the digestive tract, where resident microbes outnumber host cells by at least 10 to 1. Gut bacteria play a fundamental role in human health by promoting intestinal homeostasis, stimulating development of the immune system, providing protection against pathogens, and contributing to the processing of nutrients and harvesting of energy.1,2 The disruption of the gut microbiota has been linked to an increasing number of diseases, including inflammatory bowel disease, necrotizing enterocolitis, diabetes, obesity, cancer, allergies and asthma.1 Despite this evidence and a growing appreciation for the integral role of the gut microbiota in lifelong health, relatively little is known about the acquisition and development of this complex microbial community during infancy.3

Two of the best-studied determinants of the gut microbiota during infancy are mode of delivery and infant diet.4 Cesarean delivery perturbs normal colonization of the infant gut by preventing exposure to maternal microbes, whereas breastfeeding promotes a “healthy” gut microbiota by providing selective metabolic substrates for beneficial bacteria.4,5 Despite recommendations from the World Health Organization,6 the rate of cesarean delivery has continued to rise in developed countries and rates of breastfeeding decrease substantially within the first few months of life.7,8 In Canada, more than 1 in 4 newborns are born by cesarean delivery, and less than 15% of infants are exclusively breastfed for the recommended duration of 6 months.9,10 In some parts of the world, elective cesarean deliveries are performed by maternal request, often because of apprehension about pain during childbirth, and sometimes for patient–physician convenience.11

Gut microbiota of healthy Canadian infants: profiles by mode of delivery and infant diet at 4 months

Meghan B. Azad PhD, Theodore Konya MPH, Heather Maughan PhD, David S. Guttmann PhD, Catherine J. Field PhD, Radha S. Chari MD, Malcolm R. Sears MB, Allan B. Becker MD, James A. Scott PhD, Anita L. Kozyrskyj PhD, on behalf of the CHILD Study Investigators

See related commentary by Song and colleagues on page 373 and at www.cmaj.ca/lookup/doi/10.1503/cmaj.130147

Abstract

Background: The gut microbiota is essential to human health throughout life, yet the acquisition and development of this microbial community during infancy remains poorly understood. Meanwhile, there is increasing concern over rising rates of cesarean delivery and insufficient exclusive breastfeeding of infants in developed countries. In this article, we characterize the gut microbiota of healthy Canadian infants and describe the influence of cesarean delivery and formula feeding.

Methods: We included a subset of 24 term infants from the Canadian Healthy Infant Longitudinal Development (CHILD) birth cohort. Mode of delivery was obtained from medical records, and mothers were asked to report on infant diet and medication use. Fecal samples were collected at 4 months of age, and we characterized the microbiota composition using high-throughput DNA sequencing.

Results: We observed high variability in the profiles of fecal microbiota among the infants. The profiles were generally dominated by Actinobacteria (mainly the genus Bifidobacterium) and Firmicutes (with diverse representation from numerous genera). Compared with breastfed infants, formula-fed infants had increased richness of species, with overrepresentation of Clostridium difficile. Escherichia–Shigella and Bacteroides species were underrepresented in infants born by cesarean delivery. Infants born by elective cesarean delivery had particularly low bacterial richness and diversity.

Interpretation: These findings advance our understanding of the gut microbiota in healthy infants. They also provide new evidence for the effects of delivery mode and infant diet as determinants of this essential microbial community in early life.

Competing interests: Allan Becker is an advisory board member for Merck, Novartis and AstraZeneca; his institution has received research grants from Merck and AstraZeneca. No competing interests were declared by the other authors.

This article has been peer reviewed.

Additional CHILD Study Investigators are listed at the end of the article.

Correspondence to: Anita Kozyrskyj, kozyrsky@ualberta.ca

CMAJ 2013. DOI:10.1503/cmaj.121189
The potential long-term consequences of decisions regarding mode of delivery and infant diet are not to be underestimated. Infants born by cesarean delivery are at increased risk of asthma, obesity and type 1 diabetes,12 whereas breast-feeding is variably protective against these and other disorders.13 These long-term health consequences may be partially attributable to disruption of the gut microbiota.12,14

Historically, the gut microbiota has been studied with the use of culture-based methodologies to examine individual organisms. However, up to 80% of intestinal microbes cannot be grown in culture.3,15 New technology using culture-independent DNA sequencing enables comprehensive detection of intestinal microbes and permits simultaneous characterization of entire microbial communities. Multinational consortia have been established to characterize the “normal” adult microbiome using these exciting new methods;16 however, these methods have been underused in infant studies. Because early colonization may have long-lasting effects on health, infant studies are vital.3,4 Among the few studies of infant gut microbiota using DNA sequencing, most were conducted in restricted populations, such as infants delivered vaginally,17 infants born by

| Table 1: Characteristics of term infants in study population |
|---------------------------------------------------------------|
| **Infant** | **Age, wk** | **Sex** | **Mode of delivery** | **Premature rupture of membranes > 24 h** | **Group B streptococcal culture** | **Breastfeeding at time of fecal sampling** | **Use of antibiotics** | **Mother (timing)** | **Infant (age)** |
|------------|-------------|--------|---------------------|------------------------------------------|-----------------------------------|------------------------------------------|----------------------|----------------|----------------|
| **Vaginal delivery, not breastfeeding**                  |             |        |                     |                                          |                                   |                                          |                      |                |                |
| A          | 23          | F      | Vaginal             | No                                       | No                                 | None                                     | Cephalexin (31 WG) | Mother could not recall |                |
| B          | 18          | F      | Vaginal             | No                                       | Yes                                | None                                     | Penicillin G (labour) | None                     |                |
| C          | 22          | F      | Vaginal             | No                                       | No                                 | None                                     | None                                | Mother could not recall |                |
| D          | 15          | F      | Vaginal             | Yes                                      | No                                 | None                                     | None                                | Ampicillin and gentamicin (2 d) |                |
| E          | 13          | M      | Vaginal             | No                                       | Yes                                | None                                     | Azithromycin (20 WG); Penicillin G (labour) | None                     |                |
| F          | 23          | M      | Vaginal             | No                                       | Unknown                            | None                                     | Unknown                            | None                     |                |
| G          | 16          | M      | Vaginal             | No                                       | Yes                                | None                                     | Penicillin G (labour) | None                     |                |
| **Vaginal delivery, breastfeeding**                      |             |        |                     |                                          |                                   |                                          |                      |                |                |
| H          | 14          | F      | Vaginal             | No                                       | No                                 | Exclusive                                | None                                | None                     |                |
| I          | 17          | F      | Vaginal             | Yes                                      | No                                 | Partial                                 | None                                | None                     |                |
| J          | 15          | M      | Vaginal             | No                                       | Unknown                            | Exclusive                                | Ampicillin (after delivery) | None                     |                |
| K          | 18          | M      | Vaginal             | No                                       | No                                 | Exclusive                                | None                                | None                     |                |
| L          | 15          | M      | Vaginal             | No                                       | No                                 | Exclusive                                | None                                | None                     |                |
| M          | 21          | F      | Vaginal             | No                                       | Yes                                | Partial                                 | None                                | None                     |                |
| N          | 11          | F      | Vaginal             | No                                       | No                                 | Partial                                 | None                                | None                     |                |
| O          | 20          | F      | Vaginal             | No                                       | No                                 | Exclusive                                | None                                | None                     |                |
| P          | 19          | F      | Vaginal             | No                                       | No                                 | Exclusive                                | None                                | None                     |                |
| Q          | 21          | F      | Vaginal             | Yes                                      | No                                 | Exclusive                                | None                                | None                     |                |
| R          | 20          | M      | Vaginal             | No                                       | No                                 | Exclusive                                | None                                | None                     |                |
| **Cesarean delivery, not breastfeeding**                 |             |        |                     |                                          |                                   |                                          |                      |                |                |
| S          | 17          | F      | Cesarean, EM        | No                                       | No                                 | None                                     | Cefazolin (preop); cefazolin and metronidazole (postop) | None                     |                |
| T          | 14          | M      | Cesarean, EM        | No                                       | No                                 | None                                     | Cefazolin (postop) | None                     |                |
| **Cesarean delivery, breastfeeding**                     |             |        |                     |                                          |                                   |                                          |                      |                |                |
| U          | 15          | M      | Cesarean, EL        | No                                       | Unknown                            | Partial                                 | Cefazolin (preop) | Amoxicillin (6 wk)               |                |
| V          | 18          | M      | Cesarean, EL        | No                                       | Unknown                            | Exclusive                                | Cephalexin (postop) | None                     |                |
| W          | 18          | M      | Cesarean, EM        | No                                       | Yes                                | Partial                                 | Penicillin G (labour) | None                     |                |
| X          | 16          | M      | Cesarean, EL        | No                                       | No                                 | Exclusive                                | Clindamycin (preop) | Amoxicillin (12 wk)               |                |

Note: EL = elective, EM = emergency, preop = preoperatively, postop = postoperatively, WG = weeks gestation.
cesarean delivery who were formula-fed or preterm infants with necrotizing enterocolitis. Thus, the gut microbiota is essential to human health, yet the acquisition and development of this microbial community during infancy remains poorly understood. In the current study, we address this gap in knowledge using new sequencing technology and detailed exposure assessments of healthy Canadian infants selected from a national birth cohort to provide representative, comprehensive profiles of gut microbiota according to mode of delivery and infant diet.

Methods

Study design

This descriptive study included 24 term (37–41 weeks’ gestation) infants whose mothers were recruited at the Winnipeg, Manitoba, site of the Canadian Healthy Infant Longitudinal Development (CHILD) population-based birth cohort (www.canadianchildstudy.ca). Pregnant women were enrolled between November 2008 and August 2009. We selected the first 24 infants for whom fecal samples were available for analysis.

Figure 1: Composition of fecal microbiota in 24 healthy infants (mean age 4 mo), at the phylum (A) and family (B) level, by mode of delivery and diet. Each column represents 1 infant, as described in Table 1. BF – = no breastfeeding, BF + = exclusive or partial breastfeeding from birth until fecal sampling.
Mode of delivery, timing of membrane rupture, use of maternal antibiotics and group B streptococcus status were obtained from hospital records. Stool samples were collected from the infants at age 3–4 months. Mothers were asked to complete a questionnaire for information about infant diet (categorized as exclusive, partial or no breastfeeding) and medication use. Informed consent was obtained from parents at enrolment. This study was approved by the University of Manitoba Health Research Ethics Board.

Analysis of fecal samples

Complete protocols are included in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.121189/-/DC1). In brief, bacterial DNA was extracted from stool samples using the FastPrep DNA for Soil Kit (MP Biomedicals, Solon, Ohio), followed by high-throughput signature gene sequencing to identify individual organisms. The signature gene used was 16S rRNA, which is ubiquitous among bacteria and contains variable regions that can be used to identify individual species. The variable regions V5, V6 and V7 were amplified, sequenced and classified according to SILVA taxonomy (www.arb-silva.de), as described previously. We used quantitative polymerase chain reaction as described by Penders and colleagues for targeted analysis of Clostridium difficile because of the organism’s association with atopic allergic disease in a previous study.

Table 2: Relative abundance and frequency of dominant phyla, families and genera in fecal samples obtained at 4 months from 24 healthy Canadian infants

| Taxon*               | Relative abundance,† %, median (IQR) | Frequency, no. (%) of infants |
|----------------------|--------------------------------------|-----------------------------|
| Actinobacteria       | 36.4 (10.9–69.5)                     | 19 (79.2)                   |
| Bifidobacteriaceae   | 35.2 (0.3–68.3)                      | 18 (75.0)                   |
| Bifidobacterium      | 35.2 (0.3–68.3)                      | 18 (75.0)                   |
| Coriobacteriaceae    | 0.0 (0.0–0.6)                        | 11 (45.8)                   |
| Eggerthella          | 0.0 (0.0–0.4)                        | 8 (33.3)                    |
| Bacteroidetes        | 0.0 (0.0–0.8)                        | 9 (37.5)                    |
| Bacteroidaceae       | 0.0 (0.0–0.8)                        | 9 (37.5)                    |
| Bacteroides          | 0.0 (0.0–0.8)                        | 9 (37.5)                    |
| Proteobacteria       | 7.4 (2.8–21.5)                       | 24 (100.0)                  |
| Enterobacteriaceae   | 7.4 (2.8–20.9)                       | 24 (100.0)                  |
| Escherichia–Shigella | 5.3 (2.4–14.6)                       | 20 (83.3)                   |
| Firmicutes           | 43.8 (15.3–74.9)                     | 24 (100.0)                  |
| Clostridiaceae       | 0.1 (0.0–2.0)                        | 12 (50.0)                   |
| Clostridium          | 0.1 (0.0–2.0)                        | 12 (50.0)                   |
| Enterococcaceae      | 0.4 (0.0–1.9)                        | 15 (62.5)                   |
| Enterococcus         | 0.4 (0.0–1.9)                        | 15 (62.5)                   |
| Erysipelotrichaceae  | 0.8 (0.0–6.8)                        | 14 (58.3)                   |
| Lachnospiraceae      | 14.2 (5.7–35.8)                      | 22 (91.7)                   |
| Blautia              | 0.0 (0.0–0.6)                        | 6 (25.0)                    |
| Peptostreptococcaceae| 0.0 (0.0–1.5)                        | 11 (45.8)                   |
| Ruminococcaceae      | 0.0 (0.0–0.6)                        | 8 (33.3)                    |
| Streptococcaceae     | 1.1 (0.3–5.3)                        | 20 (83.3)                   |
| Streptococcus        | 1.1 (0.3–5.3)                        | 20 (83.3)                   |
| Veillonellaceae      | 0.9 (0.0–7.5)                        | 17 (70.8)                   |
| Veillonella          | 0.9 (0.0–7.5)                        | 16 (66.7)                   |

Note: IQR = interquartile range.
*Unclassified genera are not listed but are included within their respective family and phylum counts. Taxa present in only 1 infant or that had an interquartile range of 0.0–0.0 are omitted.
†Values represent the percentages of all 16S gene sequences analyzed, after quality processing as described in Appendix 1 (available at www.cmaj.ca/lookup/suppl/doi:10.1503/cmaj.121189/-/DC1).

Statistical analysis

In this descriptive study, we report fecal microbiome biodiversity and relative abundance of bacterial taxa according to mode of delivery and infant diet. Biodiversity measures — the Chao1 score and the Shannon diversity index — were calculated using the open-source software package QIIME (Quantitative Insights into Microbial Ecology, http://qiime.org/) with rarefied data (10 000 sequences per sample). The Chao1 score estimates the number of different species present and the Shannon diversity index evaluates both the number of species and the evenness of their distribution. Taking advantage of our sample size (larger than many in sequencing-based studies of infant gut microbiota), we performed statistical comparisons using analysis of variance, the t test, Spearman rank-order correlation or the Cochrane–Armitage χ2 test for trend, as indicated. We assessed differential abundance of bacterial taxa at the family and genus levels using Metastats (http://metastats.cbcb.umd.edu). Metastats is a statistically rigorous method designed specifically to compare microbial communities on the basis of 16S rRNA abundance data. To account for multiple testing, Metastats computes q values, which may be interpreted as p values adjusted for multiple comparisons.

Results

Study population

Fecal samples were collected from 24 healthy term infants (mean age ± standard deviation 17.4 ± 3.2 weeks). The study population comprised equal numbers of boys and girls; 6 infants (25%) were born by cesarean delivery (Table 1). At the time of sampling, 10 (42%) of the infants were exclusively breastfed, 5 (21%) were partially breastfed (supplemented with formula), and 9 (38%) were not breastfed. Exclusive breastfeeding was more common among infants born vaginally.
than among those born by cesarean delivery (44% v. 33%). Of the mothers, 11 (46%) received antibiotics during pregnancy or at delivery, including 5 (28%) of the mothers who had a vaginal delivery and all of those who had cesarean delivery. Three infants received antibiotics directly.

Profiles of gut microbiota

The relative abundance of dominant bacterial phyla, families and genera for each infant is shown in Figure 1, with median values presented in Table 2. Fecal microbiota profiles were generally dominated by the phylum Actinobacteria (median 36.4%, with representation mainly by the genus *Bifidobacterium*) and Firmicutes (median 43.8%, with diverse representation from numerous genera). A strong negative correlation was observed between these dominant phyla ($r = -0.92, p < 0.001$). Bacteria in the phylum Proteobacteria were less abundant (median 7.4%)

| Table 3: Relative abundance of dominant phyla, families and genera in fecal samples, by mode of delivery and infant diet* |

| Taxon† | Vaginal delivery, ‡%, mean ± SE | Cesarean delivery, ‡%, mean ± SE | Not breastfed, ‡%, mean ± SE | Breastfed, ‡%, mean ± SE | p value |
|--------|--------------------------------|---------------------------------|-----------------------------|--------------------------|---------|
| **Actinobacteria** | | | | | |
| Bifidobacteriaceae | 36.6 ± 7.8 | 48.6 ± 14.8 | > 0.1 | 34.4 ± 9.8 | 42.8 ± 9.4 | > 0.1 |
| *Bifidobacterium* | 36.6 ± 7.8 | 48.6 ± 14.8 | > 0.1 | 34.4 ± 9.8 | 42.8 ± 9.4 | > 0.1 |
| Coriobacteriaceae | 1.8 ± 0.9 | 0.3 ± 0.1 | > 0.1 | 1.6 ± 1.0 | 1.3 ± 0.9 | > 0.1 |
| *Eggerthella* | 0.5 ± 0.3 | 0.3 ± 0.2 | > 0.1 | 0.6 ± 0.4 | 0.4 ± 0.2 | > 0.1 |
| **Bacteroidetes** | | | | | |
| Bacteroidaceae | 1.0 ± 0.4 | 0.0 ± 0.0 | 0.03 | 0.7 ± 0.4 | 0.8 ± 0.4 | > 0.1 |
| Bacteroides | 1.0 ± 0.4 | 0.0 ± 0.0 | 0.02§ | 0.7 ± 0.4 | 0.8 ± 0.4 | > 0.1 |
| **Proteobacteria** | | | | | |
| Enterobacteriaceae | 13.7 ± 2.7 | 6.2 ± 3.1 | > 0.1 | 9.5 ± 2.6 | 13.2 ± 3.3 | > 0.1 |
| *Escherichia-Shigella* | 13.6 ± 2.7 | 1.0 ± 0.7 | < 0.001§ | 8.3 ± 2.9 | 11.8 ± 3.4 | > 0.1 |
| Pasteurellaceae | 0.1 ± 0.1 | 0.6 ± 0.6 | > 0.1 | 0.0 ± 0.0 | 0.4 ± 0.3 | 0.04 |
| *Haemophilus* | 0.1 ± 0.1 | 0.6 ± 0.6 | > 0.1 | 0.0 ± 0.0 | 0.4 ± 0.3 | 0.06 |
| **Firmicutes** | | | | | |
| Clostridiaceae | 2.8 ± 2.0 | 2.1 ± 1.0 | > 0.1 | 1.4 ± 0.5 | 3.4 ± 2.3 | > 0.1 |
| Clostridium | 2.8 ± 2.0 | 2.1 ± 1.0 | > 0.1 | 1.4 ± 0.5 | 3.4 ± 2.3 | > 0.1 |
| Enterococcaceae | 1.6 ± 0.6 | 0.9 ± 0.8 | > 0.1 | 1.8 ± 0.9 | 1.3 ± 0.5 | > 0.1 |
| *Enterococcus* | 1.6 ± 0.6 | 0.9 ± 0.8 | > 0.1 | 1.8 ± 0.9 | 1.3 ± 0.5 | > 0.1 |
| Erysipelotrichaceae | 4.6 ± 2.0 | 7.1 ± 3.8 | > 0.1 | 3.0 ± 1.1 | 6.6 ± 2.8 | > 0.1 |
| Lachnospiraceae | 22.8 ± 5.7 | 19.5 ± 6.3 | > 0.1 | 33.1 ± 8.9 | 15.3 ± 4.2 | > 0.1 |
| *Blautia* | 2.2 ± 1.4 | 5.4 ± 4.9 | > 0.1 | 4.3 ± 2.6 | 2.1 ± 2.0 | > 0.1 |
| Coprococcus | 0.9 ± 0.7 | 0.6 ± 0.6 | > 0.1 | 0.9 ± 0.5 | 0.8 ± 0.8 | > 0.1 |
| Peptostreptococcaceae | 1.2 ± 0.5 | 1.2 ± 0.7 | > 0.1 | 2.9 ± 0.8 | 0.2 ± 0.1 | 0.002§ |
| Ruminococcaceae | 0.7 ± 0.3 | 0.4 ± 0.3 | > 0.1 | 1.2 ± 0.5 | 0.2 ± 0.2 | 0.08 |
| Streptococcaceae | 4.7 ± 2.4 | 8.7 ± 6.8 | > 0.1 | 3.0 ± 1.1 | 7.3 ± 3.8 | > 0.1 |
| *Streptococcus* | 4.6 ± 2.4 | 8.7 ± 6.8 | > 0.1 | 3.0 ± 1.1 | 7.3 ± 3.8 | > 0.1 |
| Veillonellaceae | 5.0 ± 1.8 | 3.6 ± 2.0 | > 0.1 | 3.6 ± 2.2 | 5.4 ± 1.9 | > 0.1 |
| *Veillonella* | 5.0 ± 1.8 | 3.6 ± 2.0 | > 0.1 | 3.5 ± 2.2 | 5.3 ± 1.9 | > 0.1 |
| **Verrucomicrobia** | | | | | |
| Verrucomicrobiaceae | 0.6 ± 0.6 | 0.6 ± 0.6 | > 0.1 | 1.6 ± 1.2 | 0.0 ± 0.0 | 0.001§ |
| Akkermansia | 0.6 ± 0.6 | 0.6 ± 0.6 | > 0.1 | 1.6 ± 1.2 | 0.0 ± 0.0 | 0.001§ |

Note: SE = standard error.

*We assessed differential abundance of bacterial taxa using Metastats.
†Taxa were excluded from this analysis if they did not exceed 1% relative abundance in at least 1 sample or were not present in at least 3 infants.
‡Values represent the percentages of all 16S gene sequences analyzed, after quality processing as described in Appendix 1 (available at www.cmaj.ca/lookup supp/doi:10.1503/cmaj.121189/-/DC1).
§p < 0.05 after correction for multiple testing.
but were present in all of the infants. In contrast, organisms in the phylum Bacteroidetes were detected in less than half (37.5%) of the study population; this phylum was absent from all infants born by cesarean delivery, regardless of breastfeeding status (Figure 1).

Profiles of gut microbiota by mode of delivery and diet
Despite high variability between infants, we were able to detect significant effects of mode of delivery and diet on the relative abundances of several bacterial taxa (Table 3). Compared with infants who were delivered vaginally, those born by cesarean delivery had bacterial communities with significantly lower abundances of Escherichia–Shigella ($p < 0.001$, $q = 0.001$) and an absence of Bacteroides ($p = 0.02$, $q = 0.03$).

Compared with infants who were breastfed, those who were not breastfed had bacterial communities with significantly higher abundances of the family Peptostreptococcaceae ($p = 0.002$, $q = 0.01$) and the family Verrucomicrobiaceae (genus Akkermansia) ($p = 0.001$, $q = 0.01$). The prevalence of C. difficile (a member of the Peptostreptococcaceae family, not the Clostridiaceae family) was significantly lower among exclusively breastfed infants than among infants receiving formula (20% v. 71%, $p = 0.01$); the prevalence did not differ by mode of delivery.

We did not conduct stratified comparisons of delivery mode by infant diet because of small group sizes. Because few infants received antibiotics, we were unable to test for direct effects of antibiotics. We detected no significant differences according to intrapartum exposure to antibiotics, although the genus Blautia tended to be overrepresented among exposed infants (data not shown).

Based on the results from dichotomous comparisons, we conducted follow-up analyses for 3 of

![Figure 2](image-url)
the most differentially abundant taxa: Peptostreptococcaceae, Escherichia–Shigella and C. difficile (Figure 2). Exposure groups were subcategorized, with diet classified as partial, exclusive or no breastfeeding, and mode of delivery classified as vaginal, emergency cesarean or elective cesarean. Trend testing indicated that exclusivity of breastfeeding was negatively correlated with the relative abundance of Peptostreptococcaceae ($\rho = -0.64, p < 0.001$) and prevalence of $C$. difficile ($p$ for trend = 0.01). Three-group comparisons revealed that the Escherichia–Shigella lineage was underrepresented in the elective and emergency cesarean groups, attaining statistical significance in the latter compared with vaginal delivery ($p < 0.05$). Consistent with the dichotomous comparisons, there was no diet-associated trend in the relative abundance of Escherichia–Shigella and no differences associated with mode of delivery for Peptostreptococcaceae.

**Richness and diversity**

Overall, the mean rarefied Chao1 score for species richness was 12.0 (range 3–22). The mean Shannon diversity index was 1.38, ranging from 0.17 to 2.36 (Table 4). Formula-fed infants had increased richness compared with breastfed infants ($p = 0.006$) and tended to have higher diversity. When classified by mode of delivery, infants born by elective cesarean delivery had the lowest richness and diversity.

Certain taxa were correlated with bacterial richness and diversity. The relative abundance of Peptostreptococcaceae was positively correlated with both richness ($r = 0.52, p = 0.01$) and diversity ($r = 0.50, p = 0.01$). The Escherichia–Shigella abundance was negatively correlated with richness ($r = -0.41, p < 0.05$), and the genus Bifidobacterium was negatively correlated with diversity ($r = -0.57, p = 0.004$). These and other correlations are shown in Table 5.

**Interpretation**

Using new high-throughput gene sequencing technology, we have characterized the gut microbiota of healthy term infants and reported differences according to mode of delivery and infant diet. The infants included in our study were part of the CHILD national birth cohort. With its population-based sample and detailed exposure assessments, this cohort is an ideal platform from

### Table 4: Richness and diversity of fecal microbiota in infants, by early-life exposures

| Exposure                        | No. of infants | Richness score, * | $p$ value† | Diversity index, * | $p$ value† |
|---------------------------------|----------------|-------------------|------------|--------------------|------------|
| Overall                         | 24             | 12.0 ± 5.0        |            | 1.38 ± 0.53        |            |
| **Sex**                         |                |                   |            |                    |            |
| Female                          | 12             | 12.1 ± 5.0        | 0.9        | 1.37 ± 0.53        | 0.9        |
| Male                            | 12             | 11.9 ± 5.1        |            | 1.40 ± 0.56        |            |
| **Mode of delivery**            |                |                   |            |                    |            |
| Vaginal                         | 18             | 11.2 ± 4.4        | 0.007      | 1.33 ± 0.49        | 0.06       |
| Emergency cesarean              | 3              | 19.7 ± 3.2        |            | 2.02 ± 0.48        |            |
| Elective cesarean               | 3              | 9.3 ± 1.5         |            | 1.09 ± 0.47        |            |
| **Receipt of antibiotics**      |                |                   |            |                    |            |
| No                              | 19             | 11.5 ± 4.9        | 0.8        | 1.34 ± 0.55        | 0.6        |
| Yes                             | 3              | 10.7 ± 3.8        |            | 1.52 ± 0.53        |            |
| At 2 d (infant D)               | 1              | 15                |            | 1.99               |            |
| At 6 wk (infant U)              | 1              | 9                 |            | 0.95               |            |
| At 3 mo (infant X)              | 1              | 8                 |            | 1.62               |            |
| **Diet at 4 mo**                |                |                   |            |                    |            |
| Exclusively breastfed           | 10             | 9.0 ± 4.1         | 0.006      | 1.19 ± 0.51        | 0.1        |
| Partially breastfed             | 5              | 12.6 ± 5.3        |            | 1.42 ± 0.64        |            |
| Not breastfed                   | 9              | 15.0 ± 4.0        |            | 1.58 ± 0.47        |            |

Note: SD = standard deviation.

*Richness was measured with the Chao1 score, which estimates the number of different species present. Diversity was measured with the Shannon diversity index, which evaluates both the number of species and the evenness of their distribution.

†Two-tailed Student t-test or analysis of variance, with trend test for diet groups.
which to study the early-life development of the
gut microbiota. Our study addresses an important
knowledge gap, since the infant gut microbiota
has rarely been characterized with sequencing
methods that provide sufficient coverage of the
entire bacterial community.† Our findings are par-
ticularly timely given the recent affirmation of the
gut microbiota as a “super organ” with diverse
roles in health and disease,1 and the increasing
concern over rising rates of cesarean delivery and
insufficient exclusive breastfeeding in Canada.2,3

Influenced by a variety of early-life exposures,
the infant gut microbiota plays a crucial role in
lifelong health (Figure 3). Our current findings
illustrate how this essential microbial community
is modified by mode of delivery and infant diet.

We identified several groups of intestinal bacte-
ria that were differentially represented in infants
born by cesarean delivery. Most striking, the
Escherichia–Shigella lineage was underrepre-
sented, which is consistent with a previous cul-
ture-based study that reported delayed coloniza-
tion by E. coli.24 Also consistent with that report,
we found that the phylum Bacteroidetes was
undetectable in infants born by cesarean delivery.
However, contrary to previous studies,2,3 we did
not observe strong differences by mode of deliv-
ery in the prevalence of C. difficile or the relative
abundances of Bifidobacterium or Clostridium.

Bacterial richness and diversity were lowest
among infants born by elective cesarean delivery
and highest among those born by emergency
cesarean delivery. Although based on a small
number of infants, these findings suggest that col-
onization of the infant gut may be affected differ-
ently by elective versus emergency cesarean de-

delivery. Further research is warranted to determine
whether these differences are related to feeding,
antibiotics or perhaps “partial” microbial expo-
sure during emergency cesarean delivery follow-
ing membrane rupture.

Consistent with previous studies,2 our study
detected lower bacterial richness and diversity in
infants who were breastfed. This association is
generally attributed to unique oligosaccharides
found in breast milk, which serve as selective
metabolic substrates for a limited number of gut
microbes.25 We identified 2 bacterial families that
were significantly overrepresented in the infants
not receiving breast milk: Peptostreptococcaceae
and Verrucamicrobiaceae. The family Peptostrept-

tococcaceae includes C. difficile, a pathogen asso-
ciated with enteric and atopic disease.26 This
pathogen is more commonly detected in formula-
drenched than in breastfed infants,2 as confirmed by
our findings. We did not detect differential repre-
sentation of the genus Bifidobacterium according
to infant diet, as others have reported.2,21

It has been debated whether microbiota rich-
ness and diversity are clinically significant mea-
sures, or whether the prevalence of specific “benefi-
cial” organisms is more important. We found the
relative abundances of certain bacteria to be corre-
lated with overall microbiota richness and diver-
sity. These correlations were positive in some
cases and negative in others, illustrating the com-
plexity of this microbial ecosystem and reflecting
possible symbiosis or competition between spe-
cies. Further research is required to disentangle
the biological relevance of individual organisms
from that of more global diversity index measures.

Finally, similar to other sequencing-based
studies,18,26 we observed high variability of gut
microbiota between infants. This finding concurs
with previous reports in which gut microbiota
profiles varied widely in the first year of life,

Table 5: Correlation of richness and diversity of fecal microbiota with
relative abundance of dominant phyla, families and genera

| Taxon* | Richness† | Diversity‡ |
|--------|-----------|------------|
|        | Spearman r | p value    | Spearman r | p value |
| Actinobacteria | 0.04 | > 0.1 | –0.56 | 0.005 |
| Bifidobacteriaceae | 0.07 | > 0.1 | –0.57 | 0.004 |
| Bifidobacterium | 0.07 | > 0.1 | –0.57 | 0.004 |
| Coriobacteriaceae | 0.32 | > 0.1 | 0.06 | > 0.1 |
| Eggerthella | 0.44 | 0.03 | 0.11 | > 0.1 |
| Bacteroidetes | 0.98 | > 0.1 | –0.03 | > 0.1 |
| Bacteroidaceae | 0.10 | > 0.1 | –0.03 | > 0.1 |
| Bacteroides | 0.10 | > 0.1 | –0.03 | > 0.1 |
| Proteobacteria | –0.43 | 0.03 | –0.12 | > 0.1 |
| Enterobacteriaceae | –0.43 | 0.03 | –0.12 | > 0.1 |
| Escherichia–Shigella | –0.41 | 0.05 | –0.25 | > 0.1 |
| Firmicutes | 0.19 | > 0.1 | 0.60 | 0.002 |
| Clostridiaceae | 0.14 | > 0.1 | 0.51 | 0.01 |
| Clostridium | 0.14 | > 0.1 | 0.51 | 0.01 |
| Enterococcaceae | –0.08 | > 0.1 | 0.11 | > 0.1 |
| Enterococcus | –0.08 | > 0.1 | 0.11 | > 0.1 |
| Erysipelotrichaceae | 0.37 | 0.07 | 0.39 | 0.06 |
| Lachnospiraceae | 0.41 | 0.05 | 0.50 | 0.01 |
| Blautia | 0.44 | 0.03 | 0.32 | > 0.1 |
| Peptostreptococcaceae | 0.52 | 0.01 | 0.50 | 0.01 |
| Ruminococcaceae | 0.59 | 0.002 | 0.55 | 0.01 |
| Streptococcaceae | –0.01 | > 0.1 | 0.25 | > 0.1 |
| Streptococcus | –0.01 | > 0.1 | 0.25 | > 0.1 |
| Veillonellaceae | 0.04 | > 0.1 | 0.61 | 0.002 |
| Veillonella | –0.01 | > 0.1 | 0.55 | 0.01 |

*Taxa present in only 1 infant or that had an interquartile range for relative abundance of 0.0–0.0 are omitted.
†Richness was measured with the Chao1 score, which estimates the number of different species present. Diversity was measured with the Shannon Diversity Index, which evaluates both the number of species and the evenness of their distribution.
before eventually converging toward a more stable and adult-like microbiota. As others have reported, we detected a predominance of the genus Bifidobacterium in the gut microbiota of many infants. However, in our cohort, some profiles were dominated by Firmicutes, and several contained no Bifidobacterium species at all.

Strengths and limitations
The major strength of our study is the application of new high-throughput gene sequencing technology to characterize the gut microbiota of healthy infants. Our sample is representative of the Canadian infant population, with 25% born by cesarean delivery and 42% fed by exclusive breastfeeding at 4 months of age (national averages are 27% and 43%, respectively). The study was limited by a lack of longitudinal data and insufficient power for detecting differences according to antibiotic use, type of cesarean delivery or brand of infant formula. Also, we could not assess interactions between exposure variables, which are frequently inter-related (cesarean delivery is typically accompanied by prophylactic use of antibiotics and can affect breastfeeding success). In the years ahead, these deficiencies will be addressed by our ongoing analysis within the CHILD cohort, where longitudinal sampling of more than 2000 infants is anticipated and multivariable analyses will be possible. In the meantime, our subsample of 24 infants is relatively large among studies of infant gut microbiota, many of which have included fewer than 15 infants.

Conclusion
The findings of this study advance our understanding of the gut microbiota of healthy infants and illustrate how this essential microbial community can be influenced by parent and physician decisions regarding mode of delivery and infant diet.

Still, much needs to be learned about the determinants of the infant gut microbiota and associated health outcomes. First, what constitutes a healthy or “ideal” microbiota? Are bacterial richness and diversity fundamentally important, or is it more critical to acquire specific bacteria in a particular combination? Second, what additional factors drive the colonization of the infant gut? Existing studies have rarely addressed the role of family structure, maternal diet, infections during infancy or the physical environment (e.g., pets and household chemicals). Finally, how does early establishment of the gut microbiota influence health and disease later in childhood? Recent reports have linked infant gut microbiota with subsequent development of atopic disease and obesity. We ultimately plan to explore all of these associations by leveraging the comprehensive exposure assessments and clinical outcome measurements in the CHILD national birth cohort. Our current results will inform these and other investigations of the infant gut microbiota, which together hold immense potential for advancing our knowledge of the human microbiome and its role in health and disease.

References
1. Young VB. The intestinal microbiota in health and disease. Curr Opin Gastroenterol 2012;28:63-9.
2. Maynard CL, Elson CO, Hatton RD, et al. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012;489:231-41.
3. Fouhy F, Ross RP, Fitzgerald G, et al. Composition of the early intestinal microbiota: knowledge, knowledge gaps and the use of
high-throughput sequencing to address these gaps. Gut Microbes 2012;3:203-20.

4. Madan JC, Farzan SF, Hibberd PL, et al. Normal neonatal microbiome variation in relation to environmental factors, infection and allergy. Curr Opin Pediatr 2012;24:753-9.

5. Penders J, Thijs C, Vink C, et al. Factors influencing the composition of the intestinal microbiota in early infancy. Pediatrics 2006;118:511-21.

6. The World Health Organization. Global strategy for infant and young child feeding: the optimal duration of exclusive breast-feeding. Geneva (Switzerland): The Organization; 2003. Available: http://apps.who.int/ghr/pdf/pdfs/WHAS45ce544e.pdf (accessed 2012 June 6).

7. Declercq E, Young R, Cabral H, et al. Is a rising cesarean delivery rate inevitable? Trends in industrialized countries, 1987 to 2007. Birth 2011;38:99-104.

8. Kelly YJ, Watt RG. Breast-feeding initiation and exclusive duration at 6 months by social class — results from the Millennium Cohort Study. Public Health Nutr 2005;8:417-21.

9. Dettman BR, Elliott C, Heaman M, et al. Breastfeeding rates and hospital breastfeeding practices in Canada: a national survey of women. Birth 2009;36:122-32.

10. Canadian Institute for Health Information. Giving birth in Canada: national trends from 2001–2002 to 2005–2006. Ottawa (ON): The Institute; 2007. Available: https://secure.cihi.ca/free_products/childbirth_0b70725_e.pdf (accessed 2012 June 6).

11. Miesnik SR, Reale BJ. A review of issues surrounding medically elective cesarean delivery. J Obstet Gynaecol Neonatal Nurs 2007;36:560-5.

12. Neu J, Rushing J. Cesarean versus vaginal delivery: long-term infant outcomes and the hygiene hypothesis. Clin Perinatol 2011;38:321-31.

13. Schack-Nielsen L, Michaelsen KF. Breast feeding and future health. Curr Opin Clin Nutr Metab Care 2006;9:289-96.

14. Azad MB, Kozyrskyj AL. Perinatal programming of asthma: the role of gut microbiota. Clin Dev Immunol 2012;2012:932079.

15. Fraher MH, O’Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012;9:312-22.

16. Peterson J, Garges S, Giovanni M, et al. The NIH Human Microbiome Project. Genome Res 2009;19:2317-23.

17. Nakayama J, Kobayashi T, Tanaka S, et al. Aberrant structures of fecal bacterial community in allergic infants profiled by 16S rRNA gene pyrosequencing. FEMS Immunol Med Microbiol 2011;63:397-406.

18. Hong PY, Lee BW, Aw M, et al. Comparative analysis of fecal microbiota in infants with and without eczema. PLoS ONE 2010;5:e9694.

19. Mai V, Young CM, Uhanova M, et al. Fecal microbiota in premature infants prior to nectirizotone enteralcoticils. PLoS ONE 2011;6:e20647.

20. Arrandale VH, Brauer M, Brook JR, et al. Exposure assessment in cohort studies of childhood asthma. Environ Health Perspect 2011;119:591-7.

21. Maughan H, Wang PW, Diaz CJ, et al. Analysis of the cystic fibrosis lung microbiota via serial illumina sequencing of bacterial 16S rDNA hyper-variable regions. PLoS ONE 2012;7:e45791.

22. Bezirtzoglou E, Tsitsias A, Welling GW. Microbiota profile in feces of breast- and formula-fed newborns by using fluorescence in situ hybridization (FISH). Anaerobe 2011;17:478-82.

23. Roger LC, Costable A, Holland DT, et al. Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life. Microbiology 2010;156:3329-41.

24. Adlerberth I, Strachan DP, Maricurdi PM, et al. Gut microbiota and development of atopic eczema in 3 European birth cohorts. J Allergy Clin Immunol 2007;120:343-50.

25. Penders J, Thijs C, van den Brandt PA, et al. Gut microbiota composition and development of atopic manifestations in infancy: the KOALA Birth Cohort Study. Gut 2007;56:681-7.

26. Abrahamsson TR, Jakobsson HE, Andersson AF, et al. Low diversity of the gut microbiota in infants with atopic eczema. J Allergy Clin Immunol 2012;129:434-40.

27. Luoto R, Kalliomaki M, Laitinen K, et al. Initial dietary and microbiological environments deviate in normal-weight compared to overweight children at 10 years of age. J Pediatr Gastroenterol Nutr 2011;52:90-5.

28. Marcobal A, Barboza M, Froehlich JW, et al. Consumption of human milk oligosaccharides by gut-related microbes. J Agirc Food Chem 2010;58:5334-40.

29. Turroni F, Peano C, Pass DA, et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS ONE 2012;7:e36957.

30. Canadian Community Health Survey: trends in breastfeeding practices 2001 to 2009–2010. Ottawa (ON): Statistics Canada; 2008. Available: www.hc-sc.gc.ca/fn-an/preveille/nutrition/commun/prenatal/trends-tendances-eng.php (accessed 2012 June 6).

Affiliations: From the Departments of Pediatrics (Azad, Kozyrskyj), Agricultural, Food and Nutritional Sciences (Field), and Obstetrics and Gynecology (Char), University of Alberta, Edmonton, Alta.; the Dalla Lana School of Public Health (Konya, Scott) and the Centre for the Analysis of Genome Evolution and Function (Maughan, Gutmann), University of Toronto, Toronto, Ont.; the Department of Medicine (Sears), McMaster University, Hamilton, Ont.; the Department of Pediatrics and Child Health (Becker), University of Manitoba, Winnipeg, Man.; and the Manitoba Institute of Child Health (Becker, Kozyrskyj), Winnipeg, Man.

Contributors: David Gutman, James Scott and Anita Kozyrskyj conceptualized and designed the study. Malcolm Sears and the CHILD Study Investigators contributed to the design and execution of the CHILD Study. Meghan Azad analyzed data and drafted the manuscript. Theodore Konya processed samples. Heather Maughan processed sequence data. Allan Becker coordinated the recruitment of participants and the collection of samples and data. All of the authors contributed to the interpretation of data, critically reviewed the manuscript for important intellectual content and approved the final version submitted for publication.

Funding: This research was funded by the Canadian Institutes of Health Research (grant nos. 85761 and 227312), and was supported by AllerGen NCE, the Killam Trusts and Alberta Innovates — Health Solutions.

Acknowledgements: The authors extend sincere appreciation to all of the study families and the CHILD research teams. They also thank Yiye Zeng for help with the statistical analysis and Brenda Koster for bioinformatics support.

Additional CHILD Study investigators: Ryan Allen (Simon Fraser University), Dean Befus (University of Alberta), Michael Brauer (University of British Columbia), Jeff Brook (Environment Canada), Michael Cyr (McMaster University), Edith Chen (University of British Columbia), Denise Daley (James Hogg iCAPTURE Centre), Sharon Dell (Hospital for Sick Children), Judah Denburg (McMaster University), Susan Elliott (University of Waterloo), Hartmut Grasemann (Hospital for Sick Children), Kent HayGlass (University of Manitoba), Richard Hegele (University of Toronto), Linn Holness (St. Michael’s Hospital), Michael Kober (University of British Columbia), Tobias Kollmann (University of British Columbia), Catherine Laprise (Chicoutimi University Hospital), Mark Larché (McMaster University), Wen-Yi Wendy Lou (University of Toronto), Joseph Macri (McMaster University), Plush Mandhane (University of Alberta), Gregory Miller (Northwestern University), Redwan Mogbel (University of Manitoba), Theo Moraes (Hospital for Sick Children), Peter Paré (University of British Columbia), Clare Ramsey (University of Manitoba), Felix Ratjen (Hospital for Sick Children), Bruce Ritchie (University of Alberta), Andrew Sandford (James Hogg iCAPTURE Centre), Jeremy Scott (University of Toronto), Frances Silverman (University of Toronto), Padmaja Subbarao (Hospital for Sick Children), Scott Tebbutt (James Hogg iCAPTURE Centre), Tim Takaro (Simon Fraser University), Patrick Veldhuis (University of British Columbia), Teresa To (Hospital for Sick Children) and Stuart Turvey (University of British Columbia)